Showing results (21-30 of 24) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Lancet. Oncology|August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trialAndrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker ResultsAndrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.European Urology Open Science|April 8, 2024
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b StudyF Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, et al.Current Opinion in Urology|October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panelsBenjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.Pageof 3